<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920122-0103</DOCNO><DOCID>920122-0103.</DOCID><HL>   Technology Brief -- Carrington Laboratories Inc.:   U.S. Agriculture Department   Approves Use of Acemannan</HL><DATE>01/22/92</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   B.SOL CRN</CO><MS>BASIC MATERIALS (BSC)CONSUMER NON-CYCLICAL (NCY)</MS><IN>CHEMICALS, PLASTICS (CHM)DRUG MANUFACTURERS (DRG)MEDICAL SUPPLIES, EYEGLASS MANUFACTURERS (MDS)</IN><GV>AGRICULTURE DEPARTMENT (AGD)</GV><RE>BELGIUM (BEL)EUROPE (EU)NORTH AMERICA (NME)TEXAS (TX)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   Carrington Laboratories Inc., Irving, Texas, said the U.S.Department of Agriculture approved the use of its acemannandrug in conjunction with an already-available vaccine forpoultry.   The pharmaceutical concern said that its acemannan drugwill be sold by Solvay Animal Health Inc. to be used inconjunction with Solvay's vaccine for Marek's disease, achicken virus. Solvay, a unit of Solvay andamp; Cie Societe Anonymeof Brussels, will sell acemannan, a derivative of the aloevera plant, under the Solvay name.</LP><TEXT>   Carrington said research indicates that the use of itsproduct along with the traditional vaccine is more effectivethan the vaccine alone.   In American Stock Exchange composite trading yesterday,Carrington shares jumped $1.125 to close at $20.</TEXT></DOC>